Loading...
Loading...
ELTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 10.3M |
| Operating I/L | -10.3M |
| Other Income/Expense | -8.5M |
| Interest Income | 0.2M |
| Pretax | -18.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -18.8M |
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing novel immunotherapies for cancer and other diseases. The company's lead product, ELI-002, is an AMP therapeutic vaccine designed for the treatment of KRAS-driven cancers. Additionally, Elicio is working on developing other immunotherapy products such as ELI-004, ELI-007, ELI-008, ELI-005, ELI-011, and ELI-012, targeting various cancer types and diseases. These innovative immunotherapies form the core of the company's revenue generation, with a focus on addressing unmet medical needs in the market.
